康宁杰瑞-首次覆盖:全力押注双抗赛道,打造突破性的下一代肿瘤疗法-210705(40页)

VIP专免
2024-01-26 999+ 3.58MB 40 页 海报
侵权投诉
NoSuchBucket The specified bucket does not exist. 67410125021AEE343111E6F2 baogaotang.oss-cn-hongkong-internal.aliyuncs.com baogaotang 0015-00000101 https://api.aliyun.com/troubleshoot?q=0015-00000101
NoSuchBucket The specified bucket does not exist. 674101252D829D3434D25E03 baogaotang.oss-cn-hongkong-internal.aliyuncs.com baogaotang 0015-00000101 https://api.aliyun.com/troubleshoot?q=0015-00000101
NoSuchBucket The specified bucket does not exist. 67410125AB867B3836DB515D baogaotang.oss-cn-hongkong-internal.aliyuncs.com baogaotang 0015-00000101 https://api.aliyun.com/troubleshoot?q=0015-00000101
摘要:

[Table_yemei1]观点聚焦InvestmentFocus[Table_yejiao1][Table_Main]研究报告ResearchReport5Jul2021康宁杰瑞AlphamabOncology(9966HK)首次覆盖:全力押注双抗赛道,打造突破性的下一代肿瘤疗法GoingallintoBsAb,Developbreakthroughnext-generationcancertherapeutics:Initiation[Table_Info]首次覆盖优于大市InitiatewithOUTPERFORM评级优于大市OUTPERFORM现价HK$24.80目标价HK$40.70...

展开>> 收起<<
康宁杰瑞-首次覆盖:全力押注双抗赛道,打造突破性的下一代肿瘤疗法-210705(40页).pdf

共40页,预览10页

还剩页未读, 继续阅读

声明:报告堂所有资料均为用户上传分享,仅供参考学习使用,版权归原作者所有。若侵犯到您的权益,请告知我们处理!任何个人或组织,在未征得本平台同意时,禁止复制、盗用、采集、发布本站内容到任何网站、书籍等各类媒体平台。
/ 40
客服
关注